Efficacy and safety of tofacitinib, an oral janus kinase inhibitor, or adalimumab in patients with active psoriatic arthritis and an inadequate response to conventional synthetic DMARDS: A randomized, placebo-controlled, phase 3 trial

Authors
Category Primary study
ConferenceArthritis and Rheumatology
Year 2016
This article has no abstract
Epistemonikos ID: 52e90e7baa068d1a55c41dc85b64f93744c30a32
First added on: Apr 29, 2026